Page last updated: 2024-08-25

zoledronic acid and Paraganglioma

zoledronic acid has been researched along with Paraganglioma in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Auernhammer, CJ; Bechmann, N; Beuschlein, F; Bihl, M; Bornstein, SR; Broglie Däppen, M; Eisenhofer, G; Fankhauser, M; Fassnacht, M; Friemel, J; Grossman, AB; Gulde, S; Hantel, C; Helm, J; Klink, B; Knösel, T; Kroiss, M; Ladurner, R; Lauseker, M; Lottspeich, C; Maurer, J; Nölting, S; Pacak, K; Pellegata, NS; Pietzsch, J; Reincke, M; Reul, A; Richter, S; Schober, L; Schütze, I; Spoettl, G; Ullrich, M; Vetter, D; Wang, K; Weber, A; Wenter, VUJ; William, D; Ziegler, CG1

Other Studies

1 other study(ies) available for zoledronic acid and Paraganglioma

ArticleYear
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures.
    Endocrine-related cancer, 2022, 05-09, Volume: 29, Issue:6

    Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Everolimus; Humans; Mice; Paraganglioma; Pheochromocytoma; Zoledronic Acid

2022